Rodman & Renshaw initiated coverage of Cardiol Therapeutics (CRDL) with a Buy rating and $7 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >>